ATLANTA--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB: IVPH) today presented clinical data from the first part of a two-part Phase I study of its drug candidate INNO-406, a potent, oral, dual Bcr-Abl and Lyn-kinase inhibitor in patients with Chronic Myelogenous Leukemia (CML). In the study, INNO-406 was shown to be well tolerated and demonstrated activity in patients with CML who are intolerant or resistant to imatinib (Gleevec®) and multiple second generation tyrosine kinase inhibitors. The data were presented today at an oral presentation at the 49th American Society of Hematology Annual Meeting in Atlanta.
